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Abstract 
Objective: HIV‑1 rapidly establishes a persistent infection that can be contained under life‑long antiretroviral therapy 
(ART) but not cured. One major viral reservoir is the peripheral lymph node (LN) follicles. Studying the impact of 
novel HIV‑1 treatment and vaccination approaches on cells residing in germinal centers is essential for rapid progress 
towards HIV‑1 prevention and cure.
Results: We enrolled 9 asymptomatic adult volunteers with a newly diagnosed HIV‑1 infection and CD4 T cell counts 
≥ 350/ml. The patients underwent venous blood collection and inguinal lymph node excision surgery in parallel. 
Mononuclear cells were extracted from blood and tissues simultaneously. Participants were followed up regularly for 
2 weeks until complete healing of the surgical wounds. All participants completed the lymph node excision surgery 
without clinical complications. Among the 9 volunteers, one elite controller was identified. The number of mononu‑
clear cells recovered from lymph nodes ranged from 68 to 206 million and correlated positively with lymph node size. 
This is the first study to show that lymph node biopsy is a safe procedure and can be undertaken with local experts in 
rural settings. It provides a foundation for detailed immune response investigations during future clinical trials.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) has 
become one of the most serious global health challenges, 
despite intensive research over the last 30 years. In 2017, 
of the estimated 36.9 million people living with HIV 
(PLWHIV) worldwide, 19.6 million resided in eastern 
and southern Africa [1]. The UNAIDS goals of 90-90-90 
by 2020 (90% diagnosed, 90% treated, 90% virally sup-
pressed), are not yet met in Tanzania: 66% of those diag-
nosed with HIV-1 are on ART and 48% of these have 
suppressed viremia, while no numbers are published for 
the first 90 [1].
Most current vaccines provide protection by generat-
ing antibodies that neutralize pathogen entry or spread 
[2]. Numerous efforts to elicit broadly neutralizing anti-
bodies (bnAbs) against HIV in experimental animals 
and humans have been unsuccessful [3]. However, many 
HIV-1 infected patients naturally develop bnAbs that can 
effectively neutralize a broad range of HIV-1 variants and 
suppress viremia [4]. The development of such potent 
antibodies usually takes several years and is poorly 
understood as selection takes place in the germinal cent-
ers (GC) located in secondary lymphoid organs, where B 
cells closely interact with T-follicular helper cells (Tfh), 
T follicular regulatory (Tfr) cells, macrophages and fol-
licular dendritic cells [5, 6]. Studying these cell popula-
tions and their interactions is of a great importance but 
has so far been very limited, since access to those tissues 
is challenging. In humans, several markers for Tfh circu-
lating in peripheral blood have been established, includ-
ing ICOS, PD1 and CXCR5 expression [7], enabling the 
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investigation of vaccine-induced responses against vacci-
nation in peripheral blood [8, 9]. However, the functional 
and biological relationship between circulating Tfh and 
cells residing in secondary lymphoid organs is unclear 
and requires further investigation [10].
The Kilombero and Ulanga Antiretroviral Cohort 
(KIULARCO) is a single-site, open and ongoing prospec-
tive cohort of HIV-1 patients established in 2005 at the 
Chronic Diseases Clinic of Ifakara (CDCI), located at the 
Saint Francis Referral Hospital (SFRH) in Ifakara, Tanza-
nia [11]. One of the objectives of KIULARCO is to pro-
vide a platform for clinical studies on improving HIV-1 
care and treatment [12]. Here, as a proof of concept, we 
performed a lymph node excision study from asympto-
matic, chronically HIV-1-infected volunteers in this rural 
setting in Tanzania.
Main text
Results
Nine ART-naïve, HIV-1-positive volunteers were 
enrolled into the study between June and August 2018. 
Volunteers reported that they came to SFRH for reasons 
other than acute sickness or suspicion of HIV infection 
(Table  1). At enrolment, all participants were clinically 
healthy, with no fever, chills or headache recorded. The 
female-to-male ratio was 3:1 and the average age of the 
volunteers was 34 years (range 23–55 years). CD4 T-cell 
counts were on average 698 cells/ml (range 434–1302) 
and the HIV-1 viral loads, assessed at the time of diagno-
sis, measured on average 35,500 copies/ml (range < 50 to 
133,200).
For all participants the duration of infection is 
unknown, but given their asymptomatic conditions, 
relatively moderate viral loads and healthy CD4 T-cell 
counts, it is safe to assume that the participants have a 
chronic HIV-1 infection.
Interestingly, one of the volunteers (V3), who had a 
positive diagnosis for HIV-1 with two different RDTs, 
showed undetectable HIV-1 viral load (< 50 copies/ml) 
and high CD4 T-cell count (1302 cells/ml), the highest 
in this cohort. HIV-1, but not HIV-2, infection for this 
volunteer was confirmed by additional testing with a line 
immunoassay (Fig.  1) suggesting a rare elite controller 
phenotype.
Lymph node biopsies were successfully conducted from 
all 9 volunteers and the sizes of extracted nodes ranged 
from 3 to 15 mm (Fig. 2a). After extraction, LMNC were 
immediately isolated in the closely located laboratory. 
Viability of LMNC ranged from 97 to 99% and the count 
of recovered LMNC ranged from 68 to 206 million. The 
LNMC yield correlated positively with the lymph node 
size (Fig. 2b), supporting strongly that healthy secondary 
lymphoid organs were extracted. Cell samples were ali-
quoted and stored within an hour after surgical excision. 
Except for two volunteers, who developed self-resolving 
hyperaemia surrounding the incision site, none of the 
volunteers experienced any complications in relation to 
the lymph node biopsy. The incisons healed as expected 
and all volunteers were discharged from attending regu-
lar hospital visits by day 14 the latest. Volunteers started 
HIV-1 treatment on the day of enrolment in KIULARCO, 
as recommended by the national treatment guidelines of 
Tanzania.
Table 1 Demographic characteristics and clinical data of the volunteers
Volunteer ID
V1 V2 V3 V4 V5 V6 V7 V8 V9
Age 40 55 42 29 23 23 37 26 30
Gender F F F F F M F M M
BMI 18.7 22.2 28.4 24.9 21.3 23 31.6 18.8 29.7
Marital status Divorced Divorced Divorced Single Single Married Married Single Single
CD4 count 
(cells/ml)
538 662 1302 846 679 594 434 665 566
HIV‑1 RNA 
(copies/ml)
1670 68,300 < 50 8150 725 113,200 72,200 53,900 1210
Hb (g/l) 13.9 12.0 12.1 12.7 10.2 14.1 13.8 15.0 13.7
Syphilis Negative Negative Negative Negative Negative Negative Negative Negative Negative
Hepatitis B Negative Negative Negative Negative Negative Negative Negative Negative Negative
Clinical  
presentation
Healthy Healthy Healthy Healthy Healthy Healthy Healthy Healthy Healthy
Reason for 
HIV‑1 testing
Ear injury History of 
herpes zoster 
lesions
Chronic body 
malaise
Marital  
requirement
Employer 
request
Wife’s ante‑
natal clinic 
visit
Referred Voluntary 
Testing
Voluntary
Testing
Page 3 of 5Mkindi et al. BMC Res Notes          (2019) 12:561 
Discussion
Biopsies of inguinal lymph nodes together with a paired 
venous blood sample were collected from nine HIV-1 
infected patients in rural settings in Tanzania. To our 
knowledge, this is the first study of this kind in Tan-
zania. We demonstrate that this procedure is safe 
and well-tolerated with minimal adverse events that 
can resolve within 14  days after surgery. The short 
recruitment period of volunteers into the study demon-
strates that the KIULARCO cohort serves as an elegant 
platform for clinical HIV research. HIV-1 is not cura-
ble using the currently available treatment approaches, 
resulting in a growing number of PLWHIV who need 
to adhere to life-long ART treatment [13]. One of the 
common compartments for viral persistence is Tfh 
cells, making them an important target for experimen-
tal approaches to a cure for HIV [14].
A recent report by D´Souza provided an excel-
lent overview of the value of lymph node biopsies in 
the context of experimental HIV-1 vaccine trials [15]. 
Lymph node biopsies have been shown to be safe in 
HIV-1-positive volunteers, with up to 4 lymph nodes 
able to be consecutively removed from participants 
during a HIV-1 vaccine study in Thailand [16]. The bulk 
of information generated about GC development and 
responses has been derived from studies on secondary 
lymphoid tissues in mice. It is assumed that heterogene-
ity of GC Tfh cells impacts antibody isotypes produced 
by plasma blasts and long-lived memory B cells [17]. In 
humans, GC Tfh are a functionally and phenotypically 
heterogeneous population based on the expression of 
PD1, CXCR3, CCR6, CCR7 and ICOS markers [18]. 
People living in SSA are exposed to co-infections such 
as malaria and helminths, which potentially impact GC 
Tfh cell function and cytokine secretion [19]. Studying 
the environmental drivers of the functional heterogene-
ity of GC Tfh in a rural African population will provide 
essential information on HIV pathogenesis, treatment 
as well as routine and experimental vaccine monitor-
ing in a population highly affected by the HIV epidemic 
[20].
Fig. 1 Detection of HIV‑1 specific antibodies in participant V3 by a 
line immunoassay (HIV‑1 detection bands indicated in red, HIV‑2 in 
black)
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Fig. 2 a Pictures of lymph node biopsies taken from volunteers. b Positive correlation between LN size and cell yield
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Conclusions
Inguinal lymph node excisions can be safely performed 
by local experts in a rural sub-Saharan African setting, 
so long as precautions such as infection prevention are 
in place and followed carefully. Thus, the procedure 
is a feasible practice in the framework of monitoring 
novel intervention studies in HIV-1 clinical research. 
The KIULARCO cohort provides a valuable platform 
for clinical research, supporting the evaluation of novel 
interventions in a population that is highly affected by 
HIV-1 but rather neglected in relation of testing novel 
interventions.
Methods
Study site
This study was conducted in the rural communities of 
Morogoro region in Tanzania, involving two districts: 
Kilombero and Ulanga. The Chronic Diseases Clinic of 
Ifakara (CDCI) located at the St Francis Referral Hos-
pital (SFRH) runs an antiretroviral cohort (Kilombero 
and Ulanga Antiretroviral Cohort, KIULARCO). KIU-
LARCO includes all HIV-1-positive patients enrolled 
in care. SFRH has in- and outpatient services and spe-
cialized clinics including theatres with facilities needed 
for patient recruitment and lymph node extraction. The 
Ifakara Health Institute runs an advanced laboratory 
infrastructure, supporting immunological and virologi-
cal sample processing and long-term storage.
Volunteer recruitment and diagnostics
All patients seen for any health condition at SFRH are 
offered an HIV-1 test following the national strategic 
plan [11]. In 2014, SFRH adopted the WHO strategy 
for universal HIV-1 testing for all visitors, regardless of 
health condition. Routine testing for HIV-1 is done by 
a rapid diagnostic test (RDT) (SD Bioline), confirmed 
by a secondary RDT (Unigold) where necessary. HIV-1 
viral RNA plasma loads are quantified by using GenX-
pert with a detection limit of 50 copies/ml. For confir-
mation of HIV infection and differentiation between 
HIV-1 and HIV-2, the line immunoassay, INNO-LIA 
HIV I/II Score (Fujirebio, Ghent, Belgium) (Inno-Lia), 
had been used in one volunteer (V3), whose viral load 
was below the limit of detection by GenXpert.
HIV-1 positive volunteers were eligible for enrolment 
dependent on meeting the following criteria: between 
18 and 55  years of age, newly diagnosed (ART-naïve), 
CD4 T-cell count above 350 cells/ml, no active co-
morbidities, negative for hepatitis B (HBsAg), Syphi-
lis and malaria. Volunteers were informed about study 
procedures and consented to paired blood and lymph 
node removal. All volunteers were recruited into the 
KIULARCO on the same day, after consenting, and 
provided with ART treatment.
Blood sample collection and PBMC isolation
Whole blood was collected from all participants on the 
day of the LN biopsies. Plasma and serum samples were 
prepared following established procedures [12] and 
stored at − 80  °C. PBMCs were isolated by density gra-
dient centrifugation using Ficoll-Hypaque and stored in 
Fetal calf serum (FCS) with 10% DMSO in liquid nitrogen 
until further analysis.
Lymph node extraction and cell isolation
A surgical procedure to excise a single inguinal LN from 
each volunteer was performed aseptically at the SFRH 
theatre following local anaesthesia, 2% lidocaine 5 ml. An 
incision of 1–2 cm in length was made at the right or left 
inguinal area. LNs were immediately preserved in R10 
medium (RPMI with 1% Penicillin/Streptomycin and 10% 
FCS) for transport and processing. The incisions were 
sutured and patients were prescribed analgesics before 
being discharged. Patients were asked to come for three 
visits within 14 days of surgery for postoperative wound 
care. Lymph node mononuclear cells (LNMC) were 
extracted in R10 medium by mechanical disruption of 
the tissue causing cell release, followed by filtering with 
a 100un filter. Cell counts and viability were determined 
by microscopy using 0.4% trypan blue solution staining.
Limitations
The study was designed as a pilot study, therefore 
included a limited number of the participants.
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